Though Alzheimer's disease (AD) has been studied for more than a century, to date, no drug has provided a definitive cure. The slow development of the disease and the time lag between pathological changes and the appearance of symptoms make AD difficult to diagnose and result in a missed window of opportunity for effective treatment. Currently, there is still no effective treatment for the late stage of AD, though delayed onset or attenuation of symptoms is possible in the early stages of the disease. The brain barrier is composed of the blood-brain barrier and blood-CSF barrier and is a composite structure of highly selectivity permeability vessels and capillaries in the CNS. Dysfunction of the brain barrier has been confirmed in the late stage of AD; however, whether this dysfunction aggravates the development of AD in the early stage has not been investigated. In this mini-review, we review the basic structure of the brain barrier, including the various protein components and related cytokines and attempt to identify how these might potentially contribute to brain barrier dysfunction in the early stages of AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.brainresbull.2018.08.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
P-ecing together brain calcification mechanisms for therapeutic advancement.
Trends Mol Med
January 2025
Department of Biomedicine, University of Bergen, Bergen, Norway. Electronic address:
Seven primary familial brain calcification genes have been identified but their role in disease mechanisms has been less explored. Cheng et al. recently demonstrated that astrocyte-mediated regulation of brain phosphate (P) involves direct and functional interactions among three of these proteins, paving the way for new strategies to combat brain calcification.
View Article and Find Full Text PDFExosomes and non-coding RNAs: bridging the gap in Alzheimer's pathogenesis and therapeutics.
Metab Brain Dis
January 2025
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, 530000, China.
Alzheimer's disease (AD) is a neurodegenerative disease that primarily affects the elderly population and is the leading cause of dementia. Meanwhile, the vascular hypothesis suggests that vascular damage occurs in the early stages of the disease, leading to neurodegeneration and hindered waste clearance, which in turn triggers a series of events including the accumulation of amyloid plaques and Tau protein tangles. Non-coding RNAs (ncRNAs), including long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), have been found to be involved in the regulation of AD.
View Article and Find Full Text PDFTraumatic Brain Injury in Intimate Partner Violence.
Curr Pain Headache Rep
January 2025
Department of Neurology, Weill Cornell Medicine, New York Presbyterian, 525 East 68th St, RM F610, New York, NY, USA.
Purposeof Review: In this article, we explore the current literature on traumatic brain injury (TBI) in survivors of intimate partner violence (IPV) and evaluate the barriers to studying this vulnerable population.
Recent Findings: Research on TBI and IPV is limited by multiple factors including mistrust of the healthcare system by survivors, lack of awareness by community advocates, and insufficient funding by public entities. As such, most investigations are small population, retrospective, and qualitative.
Hierarchically Engineered Self-Adaptive Nanoplatform Guided Intuitive and Precision Interventions for Deep-Seated Glioblastoma.
ACS Nano
January 2025
Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
Glioblastoma multiforme (GBM), particularly the deep-seated tumor where surgical removal is not feasible, poses great challenges for clinical treatments due to complicated biological barriers and the risk of damaging healthy brain tissue. Here, we hierarchically engineer a self-adaptive nanoplatform (SAN) that overcomes delivery barriers by dynamically adjusting its structure, surface charge, particle size, and targeting moieties to precisely distinguish between tumor and parenchyma cells. We further devise a AN-uided ntuitive and recision ntervention (SGIPi) strategy which obviates the need for sophisticated facilities, skilled operations, and real-time magnetic resonance imaging (MRI) guidance required by current MRI-guided laser or ultrasound interventions.
View Article and Find Full Text PDFCorrection: Abcg2a is the functional homolog of human ABCG2 expressed at the zebrafish blood-brain barrier.
Fluids Barriers CNS
January 2025
Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 2108, Bethesda, MD, 20892, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!